Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]

Exclusion Criteria

• •Diagnosis of asthma
• •Dementia or other health issues related to memory
• •Inability to use inhalers
• •COPD due to documented α-1 antitrypsin deficiency
• •Previous treatment with triple fixed-dose combination therapy in 12 months prior to screening visit
• •Hospitalisation due to COPD exacerbation within the last 30 days prior to enrolment
• •Pregnancy or lactation period
• •Participation in an ongoing clinical interventional or observational trial for another COPD medication (or completed another trial within last 30 days of initiating BGF)
• •Patient self-reporting or a physician record with an active COVID-19 infection at time of enrolment or hospitalized due to COVID-19 infection in the last 60 days
• •Previous enrolment in this study